Ionis Pharma (IONS) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Ionis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2016
November 9, 2016 7:01 AM ESTCARLSBAD, Calif., Nov. 9, 2016 /PRNewswire/ --Â Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported income from operations of $16.1 million and a loss from operations of $87.5 million for the three and nine months ended September 30, 2016, respectively. Â The Company also reported pro forma operating income of $33.7 million and a pro forma net operating loss (NOL) of $30.5 million, both excluding non-cash stock compensation, for the same periods. Â Ionis ended the third quarter with cash, cash equivalents and short term investments of $687.8 million. Â The Company is on track to meet its pro forma NOL and cash... More
